Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Core Viewpoint - Biodesix, Inc. will release its financial results for Q4 and the full year of 2024 on March 3, 2025, followed by a conference call to discuss the results and provide a business update [1]. Company Overview - Biodesix is a leading diagnostic solutions company with five Medicare-covered tests for pulmonology patients [3]. - The Nodify Lung® Nodule Risk Assessment helps evaluate the risk of malignancy in pulmonary nodules, aiding physicians in patient triage [3]. - The IQLung™ test portfolio supports treatment decisions for lung cancer patients across all stages and facilitates personalized treatment [3]. - The company collaborates with top biopharmaceutical firms for biomarker discovery, diagnostic test development, and clinical trial support [3].